Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594386 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 258
- Enrollment target
NCT00594386 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 258 participants.
The verdict
NCT00594386, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 258 participants
- Enrollment target
Study Summary
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.
Interventions
- DRUG Rotigotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2002-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00594386
The ClinicalTrials.gov registry entry for NCT00594386 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rotigotine is the first listed.
NCT00594386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00594386 about?
NCT00594386 is a clinical study titled "An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease". The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.
What is the current status of trial NCT00594386?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 258 participants. The study started on 2002-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00594386?
The interventions under investigation include: Rotigotine (DRUG).
Who is sponsoring clinical trial NCT00594386?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.